Background
Nearly two hundred eighty million children in low and middle income countries are at risk for not achieving their full developmental potential(1). Poor development can lead to reduced scholastic ability(2) or opportunity (promoting and entrenching inequity), and has been associated with lower adult earning potential(3), and poorer health(4), thus potentially contributing to intergenerational poverty traps.
While the entire period of childhood is important for development, the first 1000 days (conception to age 2) are critically important for brain development; with the most rapid and prolific development of neural pathways, first in sensory development, then language skills and then higher cognitive functioning(5). Experiences during this period – positive or negative – can substantially impact the architecture of the developing brain. Adverse events such as exposure to familial or societal violence, toxins such as lead or arsenic, illness (anemia, diarrhea, HIV, chronic malnutrition, maternal depression), or lack of a developmentally stimulating and nurturing environment can all act as toxic stressors on young children that negatively impact cognitive development throughout the life-course(6). Infants and young children in settings of poverty are often faced with many of these stressors(7).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The IHOPE study is funded by PIVOT through a grant from the Herrnstein Family Foundation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analysed during the current study will be made public at https://dataverse.harvard.edu/dataverse/PIVOT_IHOPE upon publication. Prior to that time, datasets can be requested from the corresponding author.
